Meeting with Oncology KOLs in USA and Europe

We had the opportunity to engage with leading oncology KOLs across the USA and Europe, including Dr. Klaus Pantel, Dr. Catherine Alix-Panabières, Dr. Umberto Malapelle, and Dr. Ravindra Kolhe.

The discussions centered around our latest innovation, OncoMetastat®, and explored emerging advancements in oncology—particularly in circulating tumor cell (CTC) research and the biology of metastasis.

OncoMetastat® is our patented investigational extracorporeal blood-processing platform, inspired by blood-dialysis principles. It is designed to selectively capture circulating tumor cells directly from a patient’s bloodstream while preserving overall blood integrity. By enabling real-time interaction with CTCs, the platform aims to go beyond detection—offering the potential to study tumor behavior dynamically and generate deeper biological insights into disease progression.

Importantly, OncoMetastat® is also being evaluated for its potential to reduce circulating tumor burden through selective capture, opening new possibilities in adjunct therapeutic strategies and early intervention in the metastatic cascade. Built with a strong emphasis on precision, safety, and scalability, the technology represents a step toward integrating diagnostics and intervention within a single platform.

These insightful exchanges with global experts reinforce our commitment to advancing precision-driven cancer care through collaboration, innovation, and a deeper understanding of cancer biology.